ReviewFrontiers in cardiovascular medicine2021
Obesity and Cardiovascular Disease: The Emerging Role of Inflammation.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 56 citations in OpenAlex.
- The obesity-related chronic disease index (ORCDi), a novel composite metric to quantify ORCD burden: an ecological study across U.S. census tracts.Lancet regional health. Americas · 2026Article
- Metabolite and nutrient regulation of macrophages in obesity and metabolic disease.Nature reviews. Immunology · 2026Review
- SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation.Journal of clinical medicine · 2026Review
- Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications.Diabetology & metabolic syndrome · 2026Review
- Impact of a Hypocaloric Diet on Prognostic Biomarkers of Endothelial Dysfunction: A Prospective Study.Journal of clinical medicine · 2026Article
- Macrovascular complications in type 2 diabetes: a multiregional study in rural Bangladesh.Frontiers in endocrinology · 2026Article
- Cumulative lipid-inflammatory indices and the risk of cardiometabolic multimorbidity: a prospective cohort study.Frontiers in endocrinology · 2026Article
- Testosterone and Obesity in an Aging Society.Biomolecules · 2025Review
- Caloric restriction promotes resolution of atherosclerosis in obese mice, while weight regain accelerates its progression.The Journal of clinical investigation · 2025Article
- Article
- The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review.Current issues in molecular biology · 2025Review
- Predicting Transvaginal Surgical Mesh Exposure Outcomes Using an Integrated Dataset of Blood Cytokine Levels and Medical Record Data: Machine Learning Approach.JMIR formative research · 2025Article
- QTc Interval and Its Associated Factors in Patient With Type 2 Diabetic Mellites.Journal of diabetes research · 2025Article
- The BMIgap tool to quantify transdiagnostic brain signatures of current and future weight.Nature. Mental health · 2025Article
- Association of body composition and cardiovascular fitness with hypertension in a middle-aged adults: a cross-sectional study.Frontiers in cardiovascular medicine · 2025Article
- Correlation between Obesity and Risk Factors of Cardiovascular Diseases in Military Personnel.Iranian journal of public health · 2025Article
- Improved Systemic Inflammation is Associated with Functional Prognosis in Post-Stroke Patients.Annals of geriatric medicine and research · 2024Article
- Evaluation of the Decreased Cholesterol Potential of Levilactobacillus brevis M-10 Isolated from Spontaneously Fermented Sour Porridge in Mice with High-Cholesterol Levels.Current microbiology · 2024Article
- Optimizing Cardiovascular Health: A Comprehensive Review of Risk Assessment Strategies for Primary Prevention.Cureus · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a growing public health challenge across the globe. It is associated with increased morbidity and mortality. Cardiovascular disease (CVD) is the leading cause of mortality for people with obesity. Current strategies to reduce CVD are largely focused on addressing traditional risk factors such as dyslipidemia, type 2 diabetes (T2D) and hypertension. Although this approach is proven to reduce CVD, substantial residual risk remains for people with obesity. This necessitates a better understanding of the etiology of CVD in people with obesity and alternate therapeutic approaches. Reducing inflammation may be one such strategy. A wealth of animal and human data indicates that obesity is associated with adipose tissue and systemic inflammation. Inflammation is a known contributor to CVD in humans and can be successfully targeted to reduce CVD. Here we will review the etiology and pathogenesis of inflammation in obesity associated metabolic disease as well as CVD. We will review to what extent these associations are causal based on human genetic studies and pharmacological studies. The available data suggests that anti-inflammatory treatments can be used to reduce CVD, but off-target effects such as increased infection have precluded its broad therapeutic application to date. The role of anti-inflammatory therapies in improving glycaemia and metabolic parameters is less established. A number of clinical trials are currently ongoing which are evaluating anti-inflammatory agents to lower CVD. These studies will further clarify whether anti-inflammatory agents can safely reduce CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.